During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Latest Ratings for APLS
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Goldman Sachs | Maintains | Buy | |
| Mar 2022 | Raymond James | Maintains | Strong Buy | |
| Jan 2022 | Raymond James | Maintains | Strong Buy |
